MX2009012645A - Formulaciones y metodos para tratar el ojo seco. - Google Patents

Formulaciones y metodos para tratar el ojo seco.

Info

Publication number
MX2009012645A
MX2009012645A MX2009012645A MX2009012645A MX2009012645A MX 2009012645 A MX2009012645 A MX 2009012645A MX 2009012645 A MX2009012645 A MX 2009012645A MX 2009012645 A MX2009012645 A MX 2009012645A MX 2009012645 A MX2009012645 A MX 2009012645A
Authority
MX
Mexico
Prior art keywords
methods
dry eye
formulations
treating dry
eye
Prior art date
Application number
MX2009012645A
Other languages
English (en)
Inventor
Mark B Abelson
George W Ousler Iii
Matthew Jonathan Chapin
Original Assignee
Aciex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aciex Therapeutics Inc filed Critical Aciex Therapeutics Inc
Publication of MX2009012645A publication Critical patent/MX2009012645A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona composiciones para tratar y/o prevenir señales y síntomas asociados con el ojo seco y/o irritación ocular, y métodos para usar las mismas. Se proporcionan tales composiciones en formulaciones oftálmicas que producen bienestar en la aplicación gradual en los ojos.
MX2009012645A 2007-05-24 2008-05-23 Formulaciones y metodos para tratar el ojo seco. MX2009012645A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12480007P 2007-05-24 2007-05-24
US6615307P 2007-06-18 2007-06-18
US12480407P 2007-08-02 2007-08-02
PCT/US2008/006595 WO2008153746A1 (en) 2007-05-24 2008-05-23 Formulations and methods for treating dry eye

Publications (1)

Publication Number Publication Date
MX2009012645A true MX2009012645A (es) 2010-03-08

Family

ID=39737592

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012645A MX2009012645A (es) 2007-05-24 2008-05-23 Formulaciones y metodos para tratar el ojo seco.

Country Status (8)

Country Link
US (1) US20090010850A1 (es)
EP (1) EP2160182A1 (es)
JP (1) JP2010528014A (es)
CN (1) CN101754748A (es)
AU (1) AU2008262491A1 (es)
CA (1) CA2687717A1 (es)
MX (1) MX2009012645A (es)
WO (1) WO2008153746A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014046A2 (en) * 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
AU2009202969B1 (en) * 2009-07-23 2009-11-19 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US8778999B2 (en) * 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
EP2506831B1 (en) 2009-12-03 2013-11-20 Alcon Research, Ltd. Carboxyvinyl polymer-containing nanoparticle suspensions
EP3799866A1 (en) * 2011-04-05 2021-04-07 Optosolve Research & Development Ltd Ophthalmic treatments comprising tramadol
JP2013082682A (ja) * 2011-09-29 2013-05-09 Senju Pharmaceut Co Ltd 亜塩素酸塩を含有する水性製剤
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
TWI670057B (zh) * 2013-12-25 2019-09-01 日商日本股份有限公司Ｌｔｔ生物醫藥 治療乾眼用滴眼劑
US20170051081A1 (en) * 2014-05-02 2017-02-23 Reliance Industries Limited Apparatus for halogenation of polymer
CN105030817A (zh) * 2015-06-26 2015-11-11 江西禾氏美康药业有限公司 一种双组分复方右旋糖酐70滴眼液及其制备方法
WO2018033792A2 (en) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
CA3038528A1 (en) 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
CN111225687A (zh) * 2017-09-01 2020-06-02 默里和普尔企业有限公司 用于治疗眼科疾患的方法和组合物
EP3687524A4 (en) * 2017-09-28 2021-06-09 Medicon Pharmaceuticals, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF OPHTHALMIC DISORDERS
EP4368180A1 (en) * 2021-07-09 2024-05-15 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Application of loxoprofen sodium in preparation of drug for treating dry eye disease
WO2024071349A1 (ja) * 2022-09-29 2024-04-04 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体を含む配合剤
CN116473017B (zh) * 2023-03-22 2024-01-05 首都医科大学附属北京同仁医院 基于小鼠泪腺诱导的干燥综合征小鼠模型的造模方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230724A (en) * 1979-07-16 1980-10-28 Allergan Pharmaceuticals, Inc. Method of treating vascularization of the eye with Flurbiprofen
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
DE3612537C1 (de) * 1986-04-14 1987-07-16 Dispersa Ag Arzneimittel zur Behandlung von Entzuendungen im Auge
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5464609A (en) * 1990-03-16 1995-11-07 The Procter & Gamble Company Use of ketorolac for treatment of oral diseases and conditions
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
CN1229110C (zh) * 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
CA2477044A1 (en) * 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic formulation with gum system
US6828356B2 (en) * 2002-07-29 2004-12-07 Ast Products, Inc. Preparation of ophthalmic compositions
US6806364B2 (en) * 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
WO2004064828A1 (ja) * 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
US8008338B2 (en) * 2003-06-03 2011-08-30 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
WO2005101982A2 (en) * 2004-03-24 2005-11-03 Sun Pharmaceutical Industries Limited A stable ophthalmic composition
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
SI1885336T1 (sl) * 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
US20070166402A1 (en) * 2005-12-12 2007-07-19 Friedlaender Mitchell H Compositions, methods and kits for removing debris from an ocular area

Also Published As

Publication number Publication date
AU2008262491A1 (en) 2008-12-18
WO2008153746A1 (en) 2008-12-18
US20090010850A1 (en) 2009-01-08
CN101754748A (zh) 2010-06-23
CA2687717A1 (en) 2008-12-18
EP2160182A1 (en) 2010-03-10
JP2010528014A (ja) 2010-08-19

Similar Documents

Publication Publication Date Title
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
WO2005076998A3 (en) Rnai therapeutics for treatment of eye neovascularization diseases
WO2006105403A3 (en) Treatment of eye disorders with sirtuin modulators
WO2006127987A3 (en) Treatment of eye disorders with sirtuin modulators
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
TW200631605A (en) Ophthalmic compositions and methods for treating eyes
MXPA06014470A (es) Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas.
WO2007058935A3 (en) Ophthalmic composition for dry eye therapy
MX2009009463A (es) Preparacion de una pelicula de rapida disolucion/desintegracion que tiene una alta proporcion de ingrediente activo.
JO3358B1 (ar) معالجات حساسية العيون
EP4248971A3 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
MY172185A (en) Artificial tears and therapeutic uses
JO2795B1 (en) Immunoglobulins
PH12021550620A1 (en) Ophthalmic composition for treatment of dry eye disease
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
MY178169A (en) Topical ophthalmic peptide formulation
CY1124538T1 (el) Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης
ATE531703T1 (de) Benzochromenderivate
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
AR058141A1 (es) Composiciones topicas de n,2,3 -trimetil-2- isopropilbutamida para el alivio del dolor y metodos para usarlas
UY28202A1 (es) Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares.
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma

Legal Events

Date Code Title Description
HH Correction or change in general